Can calcitonin gene-related peptide (CGRP) and pentraxin-3 (PTX-3) be useful in diagnosing acute migraine attack?

Figures & data

Table 1. Demographic data and biomarker levels of the patient and control group.

	Patient group (n = 85)	Control group (n = 50)	p
Age (Mean ± SD)	28.38 ± 7.45	28.08 ± 6.48	0.815*
Sex (n)
Male (n = 50)	31	19	0.859*
Female (n = 85)	54	31
Presence of Aura (n, %)
Present (n = 34)	%40
Not present (n = 51)	%60
Severity of pain (Mean ± SD)	8.76 ± 1.32
Frequency of migraine attack (day/month)	1.23 ± 0.45
Serum CGRP [Median (Min–Max)] (pg/mL)	146.70 (21.52–413.67)	65.90 (3.80–256.6)	˂0.01**
Migraine with aura (n = 31)	154.71 (49.76–390.94)		0.467**
Migraine without aura (n = 54)	146.70 (21.52–413.67)
Serum PTX-3 [Median (Min-Max)] (ng/mL)	12.71 (0.62–33.97)	1.01 (0.06–9.48)	˂0.01**
Migraine with aura (n = 31)	9.26 (1.12–31.77)		0.647**
Migraine without aura (n = 54)	12.90 (0.62–33.97)

SD: Standard deviation. *Student t-test; **Mann Whitney U test.

Figure 1. ROC analysis of serum CGRP and PTX-3 levels for the diagnosis of migraine with acute attack.

Table 2. Correlation analysis of serum CGRP and PTX-3 levels with the duration of migraine headache and severity of pain.

	Spearman correlation analysis, p value
	CGRP	PTX-3	Duration of pain	Severity of pain
CGRP	–	0.525, p < 0.01	−0.625, p < 0.01	0.568, p < 0.01
PTX-3		–	−0.605, p < 0.01	0.061, p = 0.58
Duration of pain			–	−0.353, p < 0.01
Severity of pain				–

CGRP: calcitonin gene-related peptide; PTX-3; pentraxin-3.